Generative AI can unlock $60-$110B annually in Pharma & Med Products industry! ???? and will revolutionize the pharmaceutical industry. Check this post about how AI will transform Pharma. ?? Generative AI Impact: Unlocking value = 2.6% to 4.5% of annual revenues in the pharma and medical-product industries ($60B to $110B annually). ?? Improving R&D: Speeding up research and development with faster lead identification, reducing months to weeks using Generative AI techniques. ?? Automation of Screening: Foundation models automate the preliminary screening of chemicals, enabling a more precise selection of promising compounds. ?? Enhancing Indication: Identifying and prioritizing new drug indications based on clinical events and medical records, accelerating drug development. ?? Factors to Consider: Implementing human-in-the-loop processes, ensuring explainability and transparency, and addressing privacy concerns related to the use of clinical data. Embracing generative AI advancements will revolutionize drug discovery, accelerate research, and improve patient outcomes. Reference: McKinsey report "The economic potential of Generative AI: The next productivity frontier." (link in comment). Follow NanoNares Inc. Making drug development effective with better pre-clinical testing. #AIinPharma #GenerativeAI #drugdiscovery #Innovation #drugdevelopment #nanonares #preclinicalresearch
NanoNares Inc
生物技术研究
Ann Arbor，Michigan 147 位关注者
NanoNares: Making drug development effective with better preclinical testing for pharmaceutical companies.
关于我们
NanoNares Inc is a privately held company making drug development effective with better preclinical testing for pharmaceutical companies using organ on chip and predictive analytics SaaS applications. Pharmaceutical companies face a significant challenge when developing respiratory drugs. It's a long and expensive process that can take 10-15 years and cost $2.5 billion. Low success rate One of the biggest challenges is accurately predicting the efficacy of a drug before moving to clinical trials, which is where 75% of drug development costs occur. The current options available, include human cells in vitro (no organ complexity) or animal models (that are not humans), These methods have low predictability & high cost. There's an unmet need for a preclinical model that accurately predicts drug efficacy before costly clinical trials. That's where NanoNares comes in - we're providing a solution that saves time and money by accurately predicting the efficacy of respiratory drugs before clinical trials, and ultimately helps our customers bring more effective drugs to market.
- 所属行业
- 生物技术研究
- 规模
- 1 人
- 总部
- Ann Arbor，Michigan
- 类型
- 私人持股
- 领域
- Pre-clinical、Research and development、Respiratory drugs development、Organ on chip和SAAS
地点
-
主要
获取路线
US，Michigan，Ann Arbor，48103
NanoNares Inc员工
动态
-
#LinkedIn friends and colleagues: I need your help. I’m exploring approaches to enhance preclinical efficacy testing in respiratory drug development, particularly through organ-on-chip technology and AI. While I’m reaching out to gather diverse perspectives, I understand you might know other experts in this area. Would you be open to a?15-minute conversation?to share insights or refer colleagues knowledgeable in this field? Your input would be invaluable as I aim to understand industry challenges and opportunities. As a token of appreciation, I’ll share a compiled report of the industry insights gathered from these discussions, which might benefit your ongoing work. Book 15 minutes call here: https://lnkd.in/d4MebpMB Thank you for considering this request. You can tag a friend in a comment or send me a DM. P.S. a brief 15-minute conversation or a referral to a knowledgeable contact would greatly aid our efforts to understand preclinical efficacy testing better.
-